HHIP

Across TCGA pan-cancer cohorts, HHIP Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated HHIP data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher HHIP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HHIP expression acts as an unfavorable survival marker.

DLBC, OV, and SCLC are the cancer types where HHIP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
OV	OS	Median	All	0.244	0.690	.006	18	view →
SCLC	OS	Median	III,IV	0.082	0.639	<.001	12	view →
BRCA	DFS	Median	All	0.112	0.526	.005	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →
SKCM	OS	Median	III,IV	0.353	0.729	.032	3	view →
LUSC	OS	Median	All	0.217	0.518	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

HHIP–DLBC (OS)

Open the DLBC breakdown →